GB950498A - Vaccine or antigen compositions - Google Patents

Vaccine or antigen compositions

Info

Publication number
GB950498A
GB950498A GB37504/61A GB3750461A GB950498A GB 950498 A GB950498 A GB 950498A GB 37504/61 A GB37504/61 A GB 37504/61A GB 3750461 A GB3750461 A GB 3750461A GB 950498 A GB950498 A GB 950498A
Authority
GB
United Kingdom
Prior art keywords
alginate
injection
insolubilizing
vaccine
calcium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB37504/61A
Inventor
George Harry Scherr
Leslie Zaccheus Skelton
Abraham Samuel Markowitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CONS LAB Inc
Original Assignee
CONS LAB Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BE623825D priority Critical patent/BE623825A/xx
Application filed by CONS LAB Inc filed Critical CONS LAB Inc
Priority to GB37504/61A priority patent/GB950498A/en
Priority claimed from US150892A external-priority patent/US3075883A/en
Priority to DEC28202A priority patent/DE1170582B/en
Priority to DK450062AA priority patent/DK103795C/en
Priority to SE11185/62A priority patent/SE328369B/xx
Priority to CH1227262A priority patent/CH470184A/en
Priority to FR912705A priority patent/FR1505310A/en
Priority to FR912703A priority patent/FR3561M/en
Publication of GB950498A publication Critical patent/GB950498A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A composition suitable for parenteral injection intramuscularly, intradermally and subcutaneously into a living animal body comprises a substantially ungelled 1 to 5% weight/volume solution of a water-soluble alginate having the following characteristics: (a) a 5% weight/volume aqueous solution readily passes a 24 gauge needle at 20 DEG C.; (b) a 4% weight/volume aqueous solution has a viscosity less than 50 centistokes at 20 DEG C.; (c) a chemical equivalence below 250; (d) a milliosmolarity less than 150 per kg. of water on a Fiske osmometer, in a sterile aqueous medium, and containing a vaccine or antigen. It is preferred to use sodium alginate having the characteristic (a), (b) and (c) above, and (e) a pH in 4% solution between 7.2 and 7.6; (f) a millios-molarity on a Fiske osmometer of 111.5; (g) no absorption peaks on a Beckmann DK-2 recording spectrophotometer in the range of 1000-400 mm and only negligible absorption at 270 mm in the range 200 to 400 mm . The alginate is treated with C to remove pyrogens and sterilized by filtration. It is added to the vaccine or antigen and the pH adjusted to 7 to 7.8. The water-soluble alginate may be the sodium, potassium or ammonium salt of alginic acid. Upon injection insoluble alginate forms with the calcium ions present in the body fluid. In order to p ensure that the composition will gel when injected, it is preferred to adjust the concentration of insolubilizing in the composition being injected so that it is only slightly below that needed to bring about gelling. Alternatively, sequestered insolubilizing ions may be added. On injection, the sequestering agent is split by the body mechanism at the injection site so that the calcium or other ions become available for the depot production of an insoluble alginate gel. The sequestering agent must be physiologically acceptable, e.g. ethylene diamine tetraacetic acid. Suitable insolubilizing salts are the chloride, carbonate, lactate, citrate, gluconate, acetate or propionate of calcium, magnesium, barium and strontium.
GB37504/61A 1961-10-19 1961-10-19 Vaccine or antigen compositions Expired GB950498A (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
BE623825D BE623825A (en) 1961-10-19
GB37504/61A GB950498A (en) 1961-10-19 1961-10-19 Vaccine or antigen compositions
DEC28202A DE1170582B (en) 1961-10-19 1962-10-17 Carrier for parenteral vaccine and antigen compositions
DK450062AA DK103795C (en) 1961-10-19 1962-10-18 Process for the preparation of vaccine and antigen preparations using a soluble alginate.
SE11185/62A SE328369B (en) 1961-10-19 1962-10-18
CH1227262A CH470184A (en) 1961-10-19 1962-10-18 Aid for intramuscular, subcutaneous or intracutaneous parenterally injectable vaccine and antigen preparations that cause the formation of antibodies
FR912705A FR1505310A (en) 1961-10-19 1962-10-18 Manufacture of new antigen compositions
FR912703A FR3561M (en) 1961-10-19 1962-10-18 New vaccine and antigen compositions to produce increased levels of antibodies.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB37504/61A GB950498A (en) 1961-10-19 1961-10-19 Vaccine or antigen compositions
US150892A US3075883A (en) 1961-11-08 1961-11-08 Novel parenteral vaccine antigen compositions and methods of making and using

Publications (1)

Publication Number Publication Date
GB950498A true GB950498A (en) 1964-02-26

Family

ID=26263468

Family Applications (1)

Application Number Title Priority Date Filing Date
GB37504/61A Expired GB950498A (en) 1961-10-19 1961-10-19 Vaccine or antigen compositions

Country Status (7)

Country Link
BE (1) BE623825A (en)
CH (1) CH470184A (en)
DE (1) DE1170582B (en)
DK (1) DK103795C (en)
FR (2) FR3561M (en)
GB (1) GB950498A (en)
SE (1) SE328369B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7901565L (en) * 1979-02-21 1980-08-22 Pharmacia Ab Means of Immunization
CN114699364B (en) * 2022-03-29 2023-06-27 山东大学 Alginate injectable hydrogel and preparation method and application thereof

Also Published As

Publication number Publication date
DE1170582B (en) 1964-05-21
FR3561M (en) 1965-09-27
FR1505310A (en) 1967-12-15
BE623825A (en)
SE328369B (en) 1970-09-14
DK103795C (en) 1966-02-21
CH470184A (en) 1969-03-31

Similar Documents

Publication Publication Date Title
KR870003786A (en) Leaching solution of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7- (1-piperazinyl) -quinoline-3-carboxylic acid
DK3891A (en) STABILIZED ENZYME DISPERSION
SE8402550L (en) N-SUBSTITUTED DERIDATIVES OF MORANOLINE
CN1274293C (en) Ready-to-use paracetamol injection solutions containing propylene glycol as the only cosolvent
KR840005342A (en) Intravenous fluid preparation
GB950498A (en) Vaccine or antigen compositions
GB1469224A (en) Raising blood calcium level in animals
DK542089D0 (en) STORAGE STABLE LYOFIXED MDM PREPARATION AND PROCEDURE FOR PREPARING THEREOF
DE69400190D1 (en) METHOD FOR PRODUCING MEDICINAL COMPOSITIONS CONTAINING VECURONIUM BROMIDE
JPS57167919A (en) Preventing agent for intraperitoneal adhesion
US4259322A (en) Method of treatment of tuberculosis
US1870123A (en) Embalming fluid
FR2574082B1 (en) PROCESS FOR THERMAL STABILIZATION OF AQUEOUS POLYSACCHARIDE SOLUTIONS
GB903959A (en) Improvements relating to the treatment of granular soils
JPS5665079A (en) Stabilization of ground
US2364579A (en) Hog cholera vaccine
GB1339210A (en) Venous injection for safety and effective plasma substitute including artificial starch and the preparation thereof
US4742082A (en) Solution of luprostiol and 1,2,-propanediol and methods of preparation and use
GB1230157A (en)
SU64477A1 (en) The method of obtaining water-soluble drug camphor
SU709090A1 (en) Method of preparing apomorphine solution
SU143029A1 (en) The method of obtaining the drug magnesium ascorbate
SU44311A1 (en) The method of preparation of artificial blood serum
SU136852A1 (en) The method of obtaining injection solutions of indigo carmine
SU501762A1 (en) Method for preparing low molecular weight polyvinylpyrrolidone preparation